Showing results 21 - 30 of 124
Antibody-drug conjugates (ADCs) are a biotherapeutic modality typically used for the treatment of cancer....
GJE has been eagerly awaiting the decision in G 1/24 from the European Patent Office’s Enlarged Board of Appeal, which was announced yesterday. The referral relates to fundamental principles for cla...
We set out the key things for innovators and applicants to consider when patenting gene editors in Europe....
UKIPO update Series marks to be abolished As a result of the second transformation consultation by the UKIPO, it was decided that series marks would be abolished. In its press release, it was explaine...
Technology review The impact of gene therapies has been revolutionary to the treatment of genetic disorders and diseases. Unlike traditional pharmaceuticals, which typically treat symptoms, gene thera...
Read our May 2025 patent law update, including updates from the UK, the European Patent Office (EPO) and the WIPO/PCT...
From 1 May 2025, the European Union Intellectual Property Office (EUIPO) is implementing the first phase of its package of legislative changes aimed at modernising the protection of designs in the EU ...
Read our April 2025 patent law and practice updates, including updates from the UK, the European Patent Office (EPO) and the WIPO/PCT...
GJE observed the eagerly anticipated G 1/24 Enlarged Board of Appeal hearing held on 28 March 2025. The referral G 1/24 is of fundamental importance, and answers to the questions raised will be releva...
There has been recent debate about whether the established practice of the EPO to require the description to be amended to excise any matter which is not aligned with allowed claims is in fact based o...